IL2 and lung carcinoma: Previous clinical trial examined in 19 late-stage lung cancer patients revealed that SHK could reduce lung cancer growth effectively (25% in diameter), enhance patient's appetite, preserve body weight, and increase the one-year survival rate (43.3%) via increasing serum interleukin-2 level to improve the immune function [31].